These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6860730)

  • 21. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
    Kopala LC; Fredrikson D; Good KP; Honer WG
    Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777
    [No Abstract]   [Full Text] [Related]  

  • 22. Addition of antipsychotics to medication regimens during schizophrenic inpatient care.
    Koyama A; Ito H; Nakanishi M; Sawamura K; Higuchi T
    Psychiatry Clin Neurosci; 2008 Feb; 62(1):56-64. PubMed ID: 18289142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive value of insight for suicide, violence, hospitalization, and social adjustment for outpatients with schizophrenia: a prospective study.
    Yen CF; Yeh ML; Chen CS; Chung HH
    Compr Psychiatry; 2002; 43(6):443-7. PubMed ID: 12439831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Aggressiveness and residual schizophrenia].
    Manzano JM; Pereira Y; Valderrama ML; Llorca G; Ledesma A
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1992; 20(4):183-8. PubMed ID: 1529749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Intensity of psychotic symptoms and selected demographic data as predictors of effectiveness of psychotherapy of schizophrenic patients in a day-hospital treatment].
    Kamiński R; Lisiecka A
    Psychiatr Pol; 2002; 36(2):211-23. PubMed ID: 12043040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deficit in schizophrenia: the relationship between negative symptoms and neurocognition.
    Penadés R; Gastó C; Boget T; Catalán R; Salamero M
    Compr Psychiatry; 2001; 42(1):64-9. PubMed ID: 11154718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia.
    Nasrallah HA; Tandon R
    J Clin Psychiatry; 2002; 63 Suppl 13():12-20. PubMed ID: 12562142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is lack of insight associated with physically aggressive behavior among people with schizophrenia living in the community?
    Lincoln TM; Hodgins S
    J Nerv Ment Dis; 2008 Jan; 196(1):62-6. PubMed ID: 18195643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
    Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M
    Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thyrotropin-releasing hormone in schizophrenia.
    Davis KL; Hossister LE; Berger PA
    Am J Psychiatry; 1975 Sep; 132(9):951-3. PubMed ID: 808141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of chronic schizophrenics with reduced drive with Aponeuron].
    Beier R; Vehreschild T
    Psychiatr Neurol Med Psychol (Leipz); 1973 Jun; 25(6):375-9. PubMed ID: 4770515
    [No Abstract]   [Full Text] [Related]  

  • 32. Sex differences in schizophrenia.
    Chu CC; Abi-Dargham A; Ackerman B; Cetingök M; Klein HE
    Int J Soc Psychiatry; 1989; 35(3):237-44. PubMed ID: 2583957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Excretion of 5-hydroindololiloacetic acid in schizophrenics following administration of tryptophane].
    Rosengarten H; Marcjan K; Cwiertnia T
    Psychiatr Pol; 1969; 3(1):25-9. PubMed ID: 5790613
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical effects of tryptophan in chronic schizophrenic patients.
    Gillin JC; Kaplan JA; Wyatt RJ
    Biol Psychiatry; 1976 Oct; 11(5):635-9. PubMed ID: 786384
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment of aggression in schizophrenia.
    Silver H; Kushnir M
    Am J Psychiatry; 1998 Sep; 155(9):1298. PubMed ID: 9734559
    [No Abstract]   [Full Text] [Related]  

  • 36. Predicting outcome in schizophrenics and nonschizophrenics of both sexes: the Zigler-Phillips Social Competence Scale.
    Westermeyer JF; Harrow M
    J Abnorm Psychol; 1986 Nov; 95(4):406-9. PubMed ID: 3805507
    [No Abstract]   [Full Text] [Related]  

  • 37. Chronic schizophrenics in the community: are they able to report their social adjustment?
    Glazer W; Sholomskas D; Williams D; Weissman M
    Am J Orthopsychiatry; 1982 Jan; 52(1):166-71. PubMed ID: 7055223
    [No Abstract]   [Full Text] [Related]  

  • 38. Diphenylhydantoin effectiveness in the treatment of chronic schizophrenics. A double-blind controlled study with a placebo.
    Simopoulos AM; Pinto A; Uhlenhuth EH; McGee JJ; DeRosa ER
    Arch Gen Psychiatry; 1974 Jan; 30(1):106-11. PubMed ID: 4587066
    [No Abstract]   [Full Text] [Related]  

  • 39. Is levomepromazine a useful drug in treatment-resistant schizophrenia?
    Lal S; Nair NP
    Acta Psychiatr Scand; 1992 Mar; 85(3):243-5. PubMed ID: 1561898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlates of aggressive behaviour in schizophrenia: an overview.
    Cheung P; Schweitzer I
    Aust N Z J Psychiatry; 1998 Jun; 32(3):400-9. PubMed ID: 9672731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.